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This study presents in vivo evidence of ELIP targeting to inflamed arterial wall by anti-intercellular adhesion molecule-1 antibody and ultrasound-driven pioglitazone delivery into deeper layers of the arterial wall. The result is a marked decrease in atheroma formation in the peri-stent region in arteries where the ultrasound-activated therapeutic was administered.
SUMMARY
Late in-stent restenosis remains a significant problem. Bare-metal stents were implanted into peripheral arteries in miniature swine, followed by direct intra-arterial infusion of nitric oxide-loaded echogenic liposomes (ELIPs) and anti-intercellular adhesion molecule-1 conjugated ELIPs loaded with pioglitazone exposed to an endovascular catheter with an ultrasonic core. Ultrasound-facilitated delivery of ELIP formulations into stented peripheral arteries attenuated neointimal growth. Local atheroma-targeted, ultrasound-triggered delivery of nitric oxide and pioglitazone, an anti-inflammatory peroxisome proliferator-activated receptor-g agonist, into stented arteries has the potential to stabilize stent-induced neointimal growth and obviate the need for long-term (2, 3) . Stents delivering antiproliferative agents such as sirolimus and paclitaxel are effective against neointimal proliferation, but the unpredictable risk of very late stent thrombosis due to impaired re-endothelialization and delayed vascular healing remains a significant problem (4, 5) . Despite the success of drug-eluting stents in reducing in-stent restenosis in certain coronary lesions, clinical trials studying the use of drug-eluting stents in peripheral artery disease have reported disappointing long-term results (6, 7) .
These stent-related complications led investigators to evaluate other strategies for local delivery of antiproliferative or "pro-healing" drugs without the need for an implanted drug delivery system. Such strategies may allow the delivery of a drug at therapeutic doses initially without the restriction imposed by stent-based delivery systems. We have shown that local delivery of therapeutic agents could acutely stabilize atheroma and result in durable antiinflammatory effects against neointimal hyperplasia (8) . Our delivery platform is based on an echogenic liposomal formulation with targeting capabilities via surface functionalization that can be loaded with both gaseous and hydrophilic therapeutic agents and activated with ultrasound exposure for controlled payload release. Our previous studies showed the versatility of such a delivery platform in delivering bioactive gases and other therapeutic agents that are molecularly targeted to atheroma and resulted in attenuation of neointimal hyperplasia (8) , enhancing the effects of thrombolytic agents (9) and reducing the infarct size in stroke (10, 11) .
The current study used a combined endovascular ultrasound and delivery system approved by the US 
METHODS

PREPARATION AND CHARACTERIZATION OF NO-ELIPs.
The preparation of ELIPs, anti-intercellular adhesion molecule-1 (ICAM-1)-conjugated ELIPs, NO-loaded ELIPs, and PGN-loaded ELIPs has been described previously (8, (12) (13) (14) . To prepare NO-ELIPs, lipid components, Our previous study had validated the lesion characteristics by using intravascular ultrasound (IVUS) and histology (20) . Two weeks before balloon denudation, the animals were fed a hyperlipidemic diet containing 2% cholesterol and 15% lard. Oral aspirin (81 mg/d) was commenced 4 days before balloon denudation. On the day of balloon denudation, animals were sedated with tiletamine/zolazepam intramuscularly (4 mg/kg), intubated and ventilated, and anesthetized with inhaled isoflurane (1.5% to 3%). An incision was made in the right inguinal region, and the right femoral artery was exposed for insertion of a For bioanalytical assay, each harvested arterial segment was homogenized in 1 ml lysis buffer/100 mg tissue; 0.2 ml of each was extracted with an equal The degree of neointimal formation was normalized to the arterial geometry by using the intima:media ratio. In the stented segments treated with NO-ELIPs and anti-ICAM-1/PGN-ELIPs with ultrasound activation, the intima:media ratio was 29.76 AE 2.26 (9 sections); without ultrasound activation, it was 46.71 AE 4.90 (9 sections) (p < 0.001) (Figure 4) . The neointimal area of the stented arteries without ultrasound activation was 5.33 AE 1.22 mm 2 ; for those with Estimating a blood volume of 3 ml per artery, the bioavailable dose would be 4.93 mg PGN/ml or 13.8 mM. The maximally effective dose of PGN is 10 mM (24) . Liposomes have a number of unique characteristics that are particularly suited for payload delivery (25) .
The compartments of aqueous core and lipid bilayer can carry both hydrophilic and lipophilic drugs, respectively. The surface of liposomes can be modified to prolong their in vivo circulation or functionalized to display homing ligands for specific targeting (16) . ELIPs have the added feature of "gas pockets" that allow their visualization via ultrasound in molecular imaging (12, 14, 26) , serve as a reservoir for bioactive gases such as NO (8), respond to ultrasoundtriggered sonoporation for controlled drug release The degree of neointimal hyperplasia within stented segments was quantitated as the intima:media ratio in histological sections. Ultrasound-facilitated delivery of ELIP payload was effective in reducing neointimal growth within the stented arterial segments (9 sections from the control arteries vs. 9 sections from the treated cohort).
Representative histological images of stented segments treated with and without ultrasound are shown. The arrows indicate the extent of neointimal formation. Abbreviations as in Figure 2 .
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NO and PGN were chosen for their synergistic effects on restoring endothelial function, inhibiting inflammatory cellular recruitment and reducing neointimal hyperplasia. NO production is impaired in damaged endothelium after angioplasty and is responsible for de novo and in-stent restenosis (29, 30) . Stents eluting antiproliferative agents such as sirolimus and paclitaxel are more deleterious than bare-metal stents in impairing endotheliumdependent relaxation responses to acetylcholine, reducing endothelial NO synthase expression and local NO production (31, 32) . These effects lead to a failure of re-endothelialization and vascular repair, and they account for the high rates of very late stent thrombosis in association with drug-eluting stent implantation (5) .
Incorporation and local release of NO-releasing substances via stent struts may reduce platelet adhesion and intimal hyperplasia but do not solve the issues of long-term exposure to stent components.
One approach to restoring local NO production is to increase local NO synthase (NOS) activity. (38, 39) , inhibiting vascular smooth muscle migration by controlling the mitogen-activated protein kinase pathway (40, 41) , and reducing inflammation by attenuating cytokine production and nuclear factor-kB transcription activity (38, 42) . We have shown that ELIPs containing both NO and rosiglitazone could attenuate intimal proliferation in balloon-injured carotid arteries in rabbits (43) .
Adenovirus
In the current study, we improved the efficiency of Because this mode of PGN delivery is different from the water-soluble plasma distribution seen in current practice, pharmacodynamic studies are needed to confirm that the delivered dose is sufficient to provoke the desired anti-inflammatory effects. Evidence for treatment efficacy provided by this study, however, is consistent with that hypothesis. In our previous study, we showed that ultrasound activation was effective in delivering calcein-loaded immunoliposomes into all layers of the arterial wall in a miniature swine model (44) .
STUDY LIMITATIONS. Although we evaluated 9 arteries, each artery was segmented into multiple sections, yielding additional data points for IVUS and histological analyses. Fixed doses of NO and PGN, as well as one ultrasound parameter, were studied.
Optimization of the delivery strategy is still required.
NO-ELIPs and anti-ICAM-1/PGN-ELIPs were not tested independently for their therapeutic effects in the current study. However, we have evidence that pre-treatment of the artery with NO-ELIPs was absolutely necessary to facilitate the subsequent delivery of anti-ICAM-1/ELIPs into the arterial wall (14) .
Ideally, both ELIPs should be tested independently, 
